Labiotech.eu

News and Trends 7 Sep 2016

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

An American outfit from Third Rock Ventures, Fulcrum Therapeutics, has made a deal with Horizon to access its catalogue of genetic anomalies. The collaboration will target diseases arising from gene misregulation. Horizon Discovery has announced a collaboration with Fulcrum Therapeutics, launched earlier this year by Third Rock Ventures, to target diseases caused by gene regulation malfunction. Fulcrum […]

September 7, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 6 Sep 2016

Denmark: The ‘Best CEO of the World’ to retire at Year’s End

The CEO of Novo Nordisk, who was named ‘Best CEO in the World’ by the Harvard Business Review in October 2015, will not have a chance to dominate the ranking again next year. He will retire by the end of the year (and have some well-deserved holidays). Lars Sorensen, or rather, Sørensen, joined the world-leading producer […]

September 6, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 6 Sep 2016

“This Phase I could Pioneer Needle-free Vaccines”, DBV’s CEO

How annoying are needle vaccinations? Very … But the French billion-euro Biotech DBV Technologies wants to bring a paradigm shift via its Anti-allergy Patch platform! I got to chat with the founder & CEO, Pierre-Henri Benhamou, for more insights. DBV’s success continues to amaze me. It’s not only close to solving the global peanut and […]

September 6, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 6 Sep 2016

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Rigontec is taking a totally new RNA-based approach to immuno-oncology via the RIG-I receptors. The company extended its Series A fundraising to a third round, and some of the top European VC’s doubled its cash pile to almost €30M. Since launching in early 2014, Munich-based Rigontec has broken with traditional immuno-oncology and pioneered a new RNA avenue […]

September 6, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

Amgen ties up loose ends after Largest Biotech Acquisition in Germany

Before Amgen, the largest biotech company in the world, acquired Micromet in one of the splashiest biotech deals in Europe, Micromet licensed its BiTE technology to Boehringer Ingelheim. Amgen is now taking over the development of BI’s Multiple Myeloma therapy to consolidate its hold on the bispecific antibodies. Boehringer Ingelheim has handed Amgen the keys to its Bispecific T cell […]

September 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

Could Artificial Enzymes be the Future of Synthetic Chemistry?

As synthetic organic chemistry struggles to reinvent itself, the field is shifting its focus to emulating and engineering enzymes. A team of researchers in Basel has developed an artificial metalloenzyme with unique functionality that can be activated in a cell. Since the first example was published in 2015, artificial enzymes have been a hot topic […]

September 5, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 5 Sep 2016

NanoTemper: the Game-changer for Drug Development Technologies

“Getting better drugs faster” is what biochemist Dr. Stefan Duhr and biophysicist Dr. Philipp Baaske envisioned when they started building NanoTemper Technologies. Established in 2008 in Munich, NanoTemper Technologies provides innovative solutions to help develop biological products. For the past 8 years, many great products have been launched like the Monolith instruments series – providing MicroScale Thermophoresis (MST), an easy, fast […]

September 5, 2016 - 4 minutesmins - By Jerome Topsent

News and Trends 5 Sep 2016

This Parisian Biotech Startup wants to clear a Major Hurdle in Immuno-oncology

Immuno-oncology is definitely the most promising breakthrough in cancer research right now. But the main issue is  that only 20-30% of patients respond to this therapy because of a weak immune system. I met Sylvain Carlioz, the co-founder of Stimunity, who wants to solve that problem. Carlioz was working at the tech transfer office of […]

September 5, 2016 - 4 minutesmins - By Philip Hemme

News and Trends 3 Sep 2016

Mouths & their Microbiomes Grow in this London Bioart Exhibit

Anna Dumitriu’s microbial art is at once revolting and captivating. She is showcasing her latest collaborative work on mouth bacteria at the Science Gallery London. Anna Dumitriu is a UK-based bioartist fascinated by the human microbiome: she creates art to express our relationships with the communities we host. We checked in on her earlier this year […]

September 3, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 2 Sep 2016

Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success

Tecentriq could be Roche’s ticket to the top of immuno-oncology. The checkpoint inhibitor just reached its co-primary endpoints in Phase III trials for non-small cell lung cancer and could bring the company €4.5B. Roche’s Tecentriq (atezolizumab) has demonstrated that it is a force to be reckoned with by clearing Phase III clinical trials for non-small cell […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Sep 2016

Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases

From Switzerland, we depart once again, this time for Vienna. This week, we are visiting Themis Bioscience, our Biotech of the Week (and also stopping for schnitzel). City: Vienna, Austria Founded: 2009 Employees: 4 Financial Data: €10M Total Raised (as of 12/2015) CEO: Erich Tauber Mission: Themis Bioscience targets emerging diseases, like Zika and Chikungunya, and aims to develop […]

September 2, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 2 Sep 2016

This €18M Joint Venture could Scale Up Bioplastic Film Production

Roughly 300 million tons of plastic are produced globally every year, but only 700 thousand tons are bio-based and biodegradable. Carbios’s new Joint Venture aims to dramatically grow this market. Carbios has announced the formation of CARBIOLICE, a new French joint venture shared between it, Limagrain Céréales Ingrédients (a heavyweight in the field of mulching films) […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Promising Boston-based CRISPR Startup hits up Horizon to fix Gene Misregulation

Denmark: The ‘Best CEO of the World’ to retire at Year’s End

“This Phase I could Pioneer Needle-free Vaccines”, DBV’s CEO

“This 30M Series A will help us bring RNA Therapeutics to Immuno-Oncology”

Amgen ties up loose ends after Largest Biotech Acquisition in Germany

Could Artificial Enzymes be the Future of Synthetic Chemistry?

NanoTemper: the Game-changer for Drug Development Technologies

This Parisian Biotech Startup wants to clear a Major Hurdle in Immuno-oncology

Mouths & their Microbiomes Grow in this London Bioart Exhibit

Roche rockets into Checkpoint Inhibitor space with Phase III Lung Cancer Success

Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases

This €18M Joint Venture could Scale Up Bioplastic Film Production

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!